GlassScriptPhysician profile
Karan S Dixit
NPI 1225337017
$9,451.97
in general payments reported to CMS, 2019-2025
15 companies · $3,516 in 2025
The $3,516 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2021: $138 · 2023: $62.76 · 2024: $5,573 · 2025: $3,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,323 · Honoraria: $2,575 · Food and Beverage: $634 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,322.50 |
| Honoraria | $2,575.00 |
| Food and Beverage | $634.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $620.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $4,415.69 | 2024-2025 | |
| Btg International INC. | $1,428.71 | 2025 | Voraxaze |
| Catalyst Pharmaceuticals, INC. | $1,206.08 | 2025 | |
| Telix Pharmaceuticals | $1,052.68 | 2024 | Illuccix |
| Deciphera Pharmaceuticals INC. | $620.00 | 2025 | |
| Boston Scientific Corporation | $255.85 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Novocure INC. | $162.13 | 2019 | |
| Monteris Medical Corporation | $124.95 | 2021 | |
| Springworks Therapeutics, INC. | $110.19 | 2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $35.99 | 2023 | Rezlidhia, Tavalisse |
| Gt Medical Technologies, INC | $26.77 | 2023 | Gammatile |
| Abbvie INC. | $12.93 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.